Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1991 Feb;83(2):304–308. doi: 10.1111/j.1365-2249.1991.tb05632.x

Increased CD5-positive B lymphocytes in type I diabetes.

A Muñoz 1, T Gallart 1, O Viñas 1, R Gomis 1
PMCID: PMC1535266  PMID: 1704297

Abstract

CD5+ B lymphocytes have been implicated in the production of polyspecific and monospecific antibodies that bind self-antigens, and increased proportions of this B cell subset occur in patients with some autoimmune diseases. We investigated the proportion of peripheral blood CD5+ B lymphocytes in type I diabetic patients. Compared with 18 age-matched healthy subjects, 11 out of 28 (39.2%) type I diabetic patients had increased proportions of circulating CD5. B lymphocytes with no alterations in the numbers of circulating B and T lymphocytes. Although all patients with increased CD5 B lymphocytes also had serum islet cell antibodies and/or insulin autoantibodies, the occurrence of increased proportions of CD5+ B lymphocytes and serum autoantibodies was not significantly correlated. Increased proportions of CD5+ B lymphocytes was not related to the time elapsed since the clinical onset of diabetes. In addition, regardless of being increased or normal, the proportion of CD5+ B lymphocytes appeared as a relatively constant phenotype after 1 year of follow-up studies at 3-month intervals in eight patients. Although the significance of these findings remains to be established, the possibility exists that CD5+ cells play a role in the pathogenesis of type I diabetes.

Full text

PDF
304

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bergua M., Solé J., Marion G., Perez M. C., Recasens A., Fernàndez J., Casamitjana R., Gomis R. Prevalence of islet cell antibodies, insulin antibodies and hyperglycaemia in 2291 schoolchildren. Diabetologia. 1987 Sep;30(9):724–726. doi: 10.1007/BF00296996. [DOI] [PubMed] [Google Scholar]
  2. Boitard C., Bonifacio E., Bottazzo G. F., Gleichmann H., Molenaar J. Immunology and Diabetes Workshop: report on the Third International (Stage 3) Workshop on the Standardisation of Cytoplasmic Islet Cell Antibodies. Held in New York, New York, October 1987. Diabetologia. 1988 Jul;31(7):451–452. doi: 10.1007/BF00271591. [DOI] [PubMed] [Google Scholar]
  3. Bottazzo G. F., Florin-Christensen A., Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet. 1974 Nov 30;2(7892):1279–1283. doi: 10.1016/s0140-6736(74)90140-8. [DOI] [PubMed] [Google Scholar]
  4. Bottazzo G. F., Todd I., Mirakian R., Belfiore A., Pujol-Borrell R. Organ-specific autoimmunity: a 1986 overview. Immunol Rev. 1986 Dec;94:137–169. doi: 10.1111/j.1600-065X.1986.tb01168.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Braun J., Citri Y., Baltimore D., Forouzanpour F., King L., Teheranizadeh K., Bray M., Kliewer S. B-Ly1 cells: immortal Ly-1+ B lymphocyte cell lines spontaneously arising in murine splenic cultures. Immunol Rev. 1986 Oct;93:5–21. doi: 10.1111/j.1600-065x.1986.tb01499.x. [DOI] [PubMed] [Google Scholar]
  6. Bröker B. M., Klajman A., Youinou P., Jouquan J., Worman C. P., Murphy J., Mackenzie L., Quartey-Papafio R., Blaschek M., Collins P. Chronic lymphocytic leukemic (CLL) cells secrete multispecific autoantibodies. J Autoimmun. 1988 Oct;1(5):469–481. doi: 10.1016/0896-8411(88)90068-6. [DOI] [PubMed] [Google Scholar]
  7. Burastero S. E., Casali P., Wilder R. L., Notkins A. L. Monoreactive high affinity and polyreactive low affinity rheumatoid factors are produced by CD5+ B cells from patients with rheumatoid arthritis. J Exp Med. 1988 Dec 1;168(6):1979–1992. doi: 10.1084/jem.168.6.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Caligaris-Cappio F., Gobbi M., Bofill M., Janossy G. Infrequent normal B lymphocytes express features of B-chronic lymphocytic leukemia. J Exp Med. 1982 Feb 1;155(2):623–628. doi: 10.1084/jem.155.2.623. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Caligaris-Cappio F., Riva M., Tesio L., Schena M., Gaidano G., Bergui L. Human normal CD5+ B lymphocytes can be induced to differentiate to CD5- B lymphocytes with germinal center cell features. Blood. 1989 Apr;73(5):1259–1263. [PubMed] [Google Scholar]
  10. Casali P., Burastero S. E., Balow J. E., Notkins A. L. High-affinity antibodies to ssDNA are produced by CD-B cells in systemic lupus erythematosus patients. J Immunol. 1989 Dec 1;143(11):3476–3483. [PubMed] [Google Scholar]
  11. Casali P., Burastero S. E., Nakamura M., Inghirami G., Notkins A. L. Human lymphocytes making rheumatoid factor and antibody to ssDNA belong to Leu-1+ B-cell subset. Science. 1987 Apr 3;236(4797):77–81. doi: 10.1126/science.3105056. [DOI] [PubMed] [Google Scholar]
  12. Casali P., Notkins A. L. CD5+ B lymphocytes, polyreactive antibodies and the human B-cell repertoire. Immunol Today. 1989 Nov;10(11):364–368. doi: 10.1016/0167-5699(89)90268-5. [DOI] [PubMed] [Google Scholar]
  13. Casali P., Notkins A. L. Probing the human B-cell repertoire with EBV: polyreactive antibodies and CD5+ B lymphocytes. Annu Rev Immunol. 1989;7:513–535. doi: 10.1146/annurev.iy.07.040189.002501. [DOI] [PubMed] [Google Scholar]
  14. Dauphinée M., Tovar Z., Talal N. B cells expressing CD5 are increased in Sjögren's syndrome. Arthritis Rheum. 1988 May;31(5):642–647. doi: 10.1002/art.1780310509. [DOI] [PubMed] [Google Scholar]
  15. Engel P., Inglés J., de la Calle O., Gallart T. Cellular activation without proliferation to B cell growth factor and interleukin 2 in chronic lymphocytic leukaemia B cells stimulated with phorbol ester plus calcium ionophore. Clin Exp Immunol. 1989 Apr;76(1):61–67. [PMC free article] [PubMed] [Google Scholar]
  16. Freedman A. S., Boyd A. W., Bieber F. R., Daley J., Rosen K., Horowitz J. C., Levy D. N., Nadler L. M. Normal cellular counterparts of B cell chronic lymphocytic leukemia. Blood. 1987 Aug;70(2):418–427. [PubMed] [Google Scholar]
  17. Freedman A. S., Freeman G., Whitman J., Segil J., Daley J., Levine H., Nadler L. M. Expression and regulation of CD5 on in vitro activated human B cells. Eur J Immunol. 1989 May;19(5):849–855. doi: 10.1002/eji.1830190511. [DOI] [PubMed] [Google Scholar]
  18. Gobbi M., Caligaris-Cappio F., Janossy G. Normal equivalent cells of B cell malignancies: analysis with monoclonal antibodies. Br J Haematol. 1983 Jul;54(3):393–403. doi: 10.1111/j.1365-2141.1983.tb02114.x. [DOI] [PubMed] [Google Scholar]
  19. Hardy R. R., Hayakawa K., Shimizu M., Yamasaki K., Kishimoto T. Rheumatoid factor secretion from human Leu-1+ B cells. Science. 1987 Apr 3;236(4797):81–83. doi: 10.1126/science.3105057. [DOI] [PubMed] [Google Scholar]
  20. Iwatani Y., Amino N., Kaneda T., Ichihara K., Tamaki H., Tachi J., Matsuzuka F., Fukata S., Kuma K., Miyai K. Marked increase of CD5 + B cells in hyperthyroid Graves' disease. Clin Exp Immunol. 1989 Nov;78(2):196–200. [PMC free article] [PubMed] [Google Scholar]
  21. Janssen O., Gillis S., Kabelitz D. In vitro transformation by Epstein-Barr virus induces a switch in growth factor and anti-IgM responsiveness in a human leukemic B cell clone. Eur J Immunol. 1990 Jan;20(1):7–14. doi: 10.1002/eji.1830200103. [DOI] [PubMed] [Google Scholar]
  22. Kipps T. J. The CD5 B cell. Adv Immunol. 1989;47:117–185. doi: 10.1016/s0065-2776(08)60663-x. [DOI] [PubMed] [Google Scholar]
  23. Kipps T. J., Vaughan J. H. Genetic influence on the levels of circulating CD5 B lymphocytes. J Immunol. 1987 Aug 15;139(4):1060–1064. [PubMed] [Google Scholar]
  24. Lozano F., Alberola-Ila J., Places L., Gallart T., Vives J. Protein kinase C-dependent up-regulation of CD5 surface expression on normal and lymphoblastoid T cells. Immunology. 1990 Aug;70(4):434–439. [PMC free article] [PubMed] [Google Scholar]
  25. Miller R. A., Gralow J. The induction of Leu-1 antigen expression in human malignant and normal B cells by phorbol myristic acetate (PMA). J Immunol. 1984 Dec;133(6):3408–3414. [PubMed] [Google Scholar]
  26. Nakamura M., Burastero S. E., Notkins A. L., Casal P. Human monoclonal rheumatoid factor-like antibodies from CD5 (Leu-1)+ B cells are polyreactive. J Immunol. 1988 Jun 15;140(12):4180–4186. [PubMed] [Google Scholar]
  27. Nakamura M., Burastero S. E., Ueki Y., Larrick J. W., Notkins A. L., Casali P. Probing the normal and autoimmune B cell repertoire with Epstein-Barr virus. Frequency of B cells producing monoreactive high affinity autoantibodies in patients with Hashimoto's disease and systemic lupus erythematosus. J Immunol. 1988 Dec 15;141(12):4165–4172. [PubMed] [Google Scholar]
  28. Painter C. J., Monestier M., Chew A., Bona-Dimitriu A., Kasturi K., Bailey C., Scott V. E., Sidman C. L., Bona C. A. Specificities and V genes encoding monoclonal autoantibodies from viable motheaten mice. J Exp Med. 1988 Mar 1;167(3):1137–1153. doi: 10.1084/jem.167.3.1137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Palmer J. P., Asplin C. M., Clemons P., Lyen K., Tatpati O., Raghu P. K., Paquette T. L. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science. 1983 Dec 23;222(4630):1337–1339. doi: 10.1126/science.6362005. [DOI] [PubMed] [Google Scholar]
  30. Plater-Zyberk C., Maini R. N., Lam K., Kennedy T. D., Janossy G. A rheumatoid arthritis B cell subset expresses a phenotype similar to that in chronic lymphocytic leukemia. Arthritis Rheum. 1985 Sep;28(9):971–976. doi: 10.1002/art.1780280903. [DOI] [PubMed] [Google Scholar]
  31. Sthoeger Z. M., Wakai M., Tse D. B., Vinciguerra V. P., Allen S. L., Budman D. R., Lichtman S. M., Schulman P., Weiselberg L. R., Chiorazzi N. Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia. J Exp Med. 1989 Jan 1;169(1):255–268. doi: 10.1084/jem.169.1.255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Ternynck T., Avrameas S. Murine natural monoclonal autoantibodies: a study of their polyspecificities and their affinities. Immunol Rev. 1986 Dec;94:99–112. doi: 10.1111/j.1600-065x.1986.tb01166.x. [DOI] [PubMed] [Google Scholar]
  33. Werner-Favre C., Vischer T. L., Wohlwend D., Zubler R. H. Cell surface antigen CD5 is a marker for activated human B cells. Eur J Immunol. 1989 Jul;19(7):1209–1213. doi: 10.1002/eji.1830190709. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES